SCHEMBL2534009

SCHEMBL2534009

Clc1nc(C2CCCCC2)c2ccccc2n1

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
CHRNA7 P36544 1/20 0.48
PDE5A O76074 3/20 0.46
ATM Q13315 1/20 0.46
ACP1 P24666 1/20 0.42
OGG1 O15527 1/20 0.42
LCK P06239 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
NPY5R Q15761 2/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30013732 1.00 TDP1 (0.69) TDP1L3MBTL1CHRNA7PDE5AATM
SCHEMBL30249575 0.91 L3MBTL1 (0.57) TDP1L3MBTL1CHRNA7PDE5AOGG1
SCHEMBL12410052 0.91 L3MBTL1 (0.57) TDP1L3MBTL1CHRNA7PDE5AOGG1
SCHEMBL10330632 0.81 TDP1 (0.48) TDP1L3MBTL1KMT2AKDM4EALDH1A1
SCHEMBL28263786 0.81 L3MBTL1 (0.66) TDP1L3MBTL1CHRNA7PDE5AATM
SCHEMBL560134 0.80 L3MBTL1 (0.65) TDP1L3MBTL1CHRNA7PDE5AATM
SCHEMBL18943805 0.80 TDP1 (0.65) TDP1L3MBTL1CHRNA7PDE5AATM
SCHEMBL22461325 0.79 L3MBTL1 (0.51) TDP1L3MBTL1LCKNPY5RKMT2A
SCHEMBL11740420 0.78 TDP1 (0.44) TDP1L3MBTL1MAOBKMT2A
SCHEMBL30013876 0.76 TDP1 (0.60) TDP1L3MBTL1CHRNA7PDE5AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 US disclosed
EP-2003131-A1 AMINOPYRROLIDINE COMPOUND Taisho Pharmaceutical Co. Ltd. (JP) 2008-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND MC4R, MC5R, MC2R TDP1 4469/4885L3MBTL1 2918/4885CHRNA7 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.